|
Characteristics
| |
RMSTb (95%CI)
|
HRc (95%CI)
|
P valuea
|
Interaction p
|
|---|
|
Non-chemotherapy
|
Chemotherapy
|
|---|
|
Total
|
–
|
53.8 (51.7–55.3)
|
56.2 (50.1–57.1)
|
0.775 (0.355–1.691)
|
0.521
|
–
|
|
Sex
|
Male
|
53.2 (50.7–55.3)
|
55.9 (54.4–57.1)
|
0.748 (0.259–2.164)
|
0.591
|
0.805
|
|
Female
|
54.5 (51.3–56.5)
|
56.8 (55.0–58.0)
|
0.819 (0.260–2.585)
|
0.733
| |
|
Age (years)
|
≤55
|
54.3 (47.9–57.4)
|
56.3 (54.2–57.7)
|
0.384 (0.074–1.999)
|
0.237
|
0.371
|
|
56–60
|
55.4 (47.4–58.5)
|
56.8 (54.2–58.3)
|
2.720 (0.001–16.94)
|
0.510
| |
|
61–65
|
53.3 (46.5–57.0)
|
55.7 (52.8–57.4)
|
1.375 (0.159–11.91)
|
0.772
| |
|
66–70
|
53.2 (48.2–56.3)
|
57.3 (53.7–58.8)
|
0.015 (0.001–19.84)
|
0.023
| |
|
> 70
|
53.6 (50.6–55.8)
|
54.6 (50.0–57.2)
|
2.409 (0.486–11.96)
|
0.266
| |
|
Size (cm)
|
≤5.0
|
54.0 (51.3–55.9)
|
56.1 (54.6–57.2)
|
1.089 (0.364–3.259)
|
0.878
|
0.294
|
|
> 5.0
|
53.7 (50.4–55.8)
|
56.3 (54.4–57.5)
|
0.554 (0.178–1.721)
|
0.300
| |
|
Differentiation
|
Well-moderate
|
53.9 (51.9–55.4)
|
56.3 (55.1–57.2)
|
0.777 (0.332–1.822)
|
0.561
|
0.669
|
|
Poor
|
52.0 (43.1–56.2)
|
54.7 (47.5–58.1)
|
0.894 (0.125–6.367)
|
0.911
| |
|
T category
|
3
|
56.4 (54.1–58.0)
|
57.6 (55.4–58.7)
|
0.827 (0.137–4.990)
|
0.836
|
0.616
|
|
4
|
51.8 (48.7–54.0)
|
55.6 (54.2–56.7)
|
0.717 (0.302–1.705)
|
0.450
| |
|
CEAd (ng/mL)
|
< 5
|
54.6 (51.9–56.6)
|
56.8 (55.3–57.8)
|
0.721 (0.228–2.280)
|
0.576
|
0.663
|
|
≥5
|
53.5 (50.2–55.7)
|
55.1 (52.6–56.8)
|
1.047 (0.294–3.726)
|
0.944
| |
|
Examined lymph nodes
|
< 12
|
52.0 (47.8–54.9)
|
53.6 (50.4–55.7)
|
0.857 (0.245–2.996)
|
0.809
|
0.962
|
|
≥12
|
54.4 (52.2–56.1)
|
57.1 (55.9–57.9)
|
0.860 (0.311–2.376)
|
0.771
| |
|
PLRe
|
≤130
|
56.0 (53.7–57.6)
|
56.0 (54.4–57.1)
|
1.443 (0.381–5.464)
|
0.587
|
0.245
|
|
> 130
|
51.3 (48.2–53.8)
|
56.5 (54.9–57.8)
|
0.506 (0.183–1.397)
|
0.180
| |
- a P value of the log-rank test
- b RMST: the restricted mean survival time
- c HR: Hazard Ratio, chemotherapy patients vs. non-chemotherapy patients
- d CEA: carcinoembryonic antigen
- e PLR: platelet to lymphocyte ratio
